Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is conducted in Asia. The aim of this observational study is to evaluate the current status of diabetes management, control, and complications in diabetic subjects in Asia.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| A |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| No treatment given | Other | Subject will only fill out a questionaire when entering the observational study. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Mean age of onset of type 1 and type 2 diabetes mellitus | at baseline visit/study start | |
| Mean duration of treatment of type 2 diabetes mellitus. | at baseline visit/study start | |
| Percentage of patients on Insulin and Oral Anti-Diabtetics Drug (OADs) therapy, respectively | at baseline visit/study start | |
| Mean duration of diabetes in type 1 and type 2 patients respectively | at baseline visit/study start | |
| Mean FPG (fasting plasma glucose),PPG (post prandial glucose) and HbA1c of diabetic patients. | at baseline visit/study start | |
| Percentage of diabetic patients with HbA1c target below 7.0% and below 6.5%, respectively | at baseline visit/study start | |
| Percentage of diabetic patients having dyslipidemia and hypertension, cardiovascular complications, peripheral vascular disease, diabetic nephropathy and diabetic eye complications, respectively | at baseline visit/study start |
| Measure | Description | Time Frame |
|---|---|---|
| Patients' perception will be analysed through Patient questionnaire measuring: Psychological well-being, Quality of life and Patients' compliant to treatment | at baseline visit/study start | |
| Physician perception of diabetes and its management will be analysed through physician questionnaire measuring awareness about: HbA1c test and its goal, anti-diabetic treatment, barriers towards optimum diabetes control |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Patients with diabetes mellitus (both type 1 and type 2) being treated at general hospitals, diabetes clinics and referral clinics will be selected according to the inclusion and exclusion criteria.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Global Clinical Registry (GCR, 1452) | Novo Nordisk A/S | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Novo Nordisk Investigational Site | Taipei | Taiwan |
Not provided
| Label | URL |
|---|---|
| Clinical Trials at Novo Nordisk | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D003922 | Diabetes Mellitus, Type 1 |
| D003924 | Diabetes Mellitus, Type 2 |
| ID | Term |
|---|---|
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Capillary or venous blood will be drawn for analysing HbA1c.
| at baseline visit/study start |
| Duration of diabetes associated with highest number of diabetic complications | at baseline visit/study start |
| Minimum duration of diabetes associated with 10% incidence of diabetic complications (CVD, Nephropathy and retinopathy) | at baseline visit/study start |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |